1306638-12-9
Chemical Structure
ML089
- CAS No.: 1306638-12-9
- Formula:C13H8FNOS
- Molecular Weight:245.27
IUPAC Name: 5-fluoro-2-phenylbenzo[d]isothiazol-3(2H)-one
InChIKey: ZTQXZKHEMCRFEP-UHFFFAOYSA-N
SMILES: O=C1N(C2=CC=CC=C2)SC3=C1C=C(F)C=C3
Biological Activity: ML089 is an orally active inhibitor of phosphomannose isomerase (PMI) and PHOSPHO1, with an IC50 value of 1.3 μM against human PMI and an IC50 value of 0.8 μM against PHOSPHO1. ML089 blocks the catabolism of mannose-6-phosphate, directs mannose-6-phosphate to participate in protein glycosylation, increases mannose incorporation into cellular proteins, and reduces tritiated water production from mannose-6-phosphate. ML089 inhibits PMI in living cells. ML089 can be used in research related to congenital disorder of glycosylation type Ia (CDG-Ia)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ML089 | 99.98% | ML089 is an orally active inhibitor of phosphomannose isomerase (PMI) and PHOSPHO1, with an IC50 value of 1.3 μM against human PMI and an IC50 value of 0.8 μM against PHOSPHO1. ML089 blocks the catabolism of mannose-6-phosphate, directs mannose-6-phosphate to participate in protein glycosylation, increases mannose incorporation into cellular proteins, and reduces tritiated water production from mannose-6-phosphate. ML089 inhibits PMI in living cells. ML089 can be used in research related to congenital disorder of glycosylation type Ia (CDG-Ia). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hedrick M, et al. Therapeutic Inhibitors of Phosphomannose Isomerase - Probe 1. 2009 Apr 21 [updated 2010 Sep 2]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. [Content Brief]
- [2]. Dahl R, et al. Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. Journal of medicinal chemistry. 2011 May 26;54(10):3661-8. [Content Brief]
Keywords
